TrialBlood2010

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

Farhad Ravandi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.